ICMR invites EoI for commercialization of RT PCR assay for detection of Influenza A, B, SARS CoV2
The Indian Council of Medical Research (ICMR) has invited Expression of Interest (EoI) through email from experienced Indian agencies for undertaking Transfer of Technology for commercialization and marketing of multiplex single tube real time RT PCR assay for detection of Influenza A , B and SARS CoV2.
The EoI document containing the details of qualification criteria, submission details, brief objective and scope of work and evaluation criteria etc. can be downloaded from the ICMR website (https://www.icmr.gov.in). Last date of submission is June 14, 2023.
Due to the current COVID-19 situation, the EoI may be submitted through email to sadhana_s@ymail.com and wasona.hq@icmr.gov.in. Shortlisted firms/organisation shall only be contacted for the further process of Technology Transfer.
ICMR-National Institute of Virology (ICMR-NIV), one of the constituent institutes of the ICMR has developed a technology entitled “Multiplex single tube Real time RT PCR assay for detection of Influenza A, B and SARS CoV2” (hereinafter) referred to as “Technology”.
ICMR is lawfully entitled to enter into any form of non-exclusive agreements with experienced manufacturing companies hereinafter referred to as the “Company”/“licensee” through a defined agreement for Licensing/Commercialization of Combo RT-PCR Kit , hereinafter referred to as the ‘Product’.
The scope of work stipulates that ICMR is willing to transfer the said Technology to the Company on an upfront license fee and royalty basis on a fixed term contract for manufacturing and marketing of the Technology.
The upfront /licensing fees for the Technology shall be determined by a Committee constituted by ICMR having Technical experts from the Institute developing the technology and representative from ICMR headquarters and external subject specific experts on the basis of technology readiness level (TRL),technology valuation etc.
The company would be granted rights to undertake manufacture, sell, and commercialize the product viz Combo RT-PCR Kit under defined agreement.
An Agreement following EoI is proposed to be executed on a “Non-Exclusive” basis with single/multiple companies to enable wider outreach of the Combo RT-PCR Kit for societal benefit.
ICMR-National Institute of Virology (ICMR-NIV) has expertise in various techniques, methods and information relating to aforesaid technology which could be used for the production of Combo RT-PCR kit.
ICMR-NIV Institute will provide expert guidance & technical support for the production of Combo RT-PCR Kit, in all phases. Such technical oversight by ICMR-NIV Institute would accelerate the development of the product and its commercialization.
Source : 1
AuroBlog | Clinical Research Blog | Aurous HealthCare CRO, India 